Fiona Cauley ( https://www.fionacauley.com ) is a Nashville-based comedy superstar who uses her comedy for a greater purpose – to raise awareness about her rare, genetic disease, Friedreich's Ataxia (FA), that progressively damages the nervous system, causing loss of muscle control over time, and is found in approximately one in 50,000 people worldwide (5,000 individuals in the United States and 15,000 worldwide).
Diagnosed at just 18 with this degenerative neurological condition, Fiona transformed adversity not just into an amazing career in comedy, but also beyond the stage, as an extremely powerful voice for disability visibility—sharing her story in conversations on podcasts and shows, and using comedy to foster understanding and empathy.
Fiona’s style has been defined as both fearless and impactful. She tackles everything from dating while in a wheelchair, to confronting audience discomfort and all sorts of stigma head-on.
Dr. Lynch maintains a dynamic program focused on the Friedreich's Ataxia, which spans clinical, translational, and basic science research efforts on FA that include conducting double-blind clinical trials, identifying biomarkers, and leading mechanistic studies in animal and cellular models of FA.
The research conducted by Dr. Lynch and his lab team have led to a greater understanding of the metabolic dysfunction underlying FA. Their work has led to the creation of a patient database as well as a pipeline of more than 20 drug candidates that represent potential new therapies. Dr. Lynch is currently working with pharmaceutical industry partners to develop drug candidates as well as biomarkers for FA.
Dr. Lynch has a Medical Degree, and a Ph.D. in Neuroscience, from Johns Hopkins University School of Medicine, Baltimore.
people designing a better tomorrow for all of us.
I'm your host, Ira Penster.
Welcome, everybody, again to another episode of our show, bringing you not one, but two
really awesome guests today.
First, we have the honor of being joined by comedy superstar Fiona Paulley.
She has been performing all over the place in her hometown of Nashville and Austin and
Houston, just wrapped up touring with Nikki Glaser.
But Fiona is more than a comedian.
She uses her comedy for a greater purpose, and that is to raise awareness of her rare
genetic disease known as Friedrich ataxia, which is found in around 5,000 individuals
here in the United States, about 15,000 worldwide.
Fiona was diagnosed at just 18, but she transformed her adversity into this amazing career in
comedy, but also beyond the stage, and she's really a powerful voice for disability visibility,
sharing her story on various shows, podcasts, fostering understanding and empathy.
We also have the honor of being joined by Dr. David Lynch, who is attending neurologist
in the Division of Neurology down the street here at Children's Hospital Philadelphia,
and director of their Friedrich ataxia program.
He has a really dynamic program focused on FA, spans everything from clinical development,
translational development, basic science that ultimately is often clinical trials, identifying
biomarkers, mechanistic studies, and ultimately focused on developing a potentially amazing
pipeline of new drug candidates for this condition, did both his PhD and M.D. at Johns
Hopkins University.
A lot of really cool topics to get into today, I'm really honored to have them both with
us.
Fiona Cawley, Dr. David Lynch, thank you so much for coming on the show today.
Thank you.
Yeah, thank you for having us.
It's awesome having both of you, really, really interesting set of topics.
Fiona, I'd love to start off with you.
As mentioned in the bio, you were diagnosed when you were 18, but I believe you started
experiencing the very symptoms of FA when you were a couple of years before.
I read a little story about how, I guess, your principal at your elementary school thought
you were drinking during in-beginning classes.
Take us back a bit, if you would, and tell us the introductory story here, if you would.
Yeah.
So, I started showing symptoms around 14 or 15 years old, but no one in my family has
ever had any kind of disability, so that was not on the radar.
And I am a middle child, which is important for this story, I think.
Prior to symptoms showing up, I was a big athlete.
Everyone assumed that would be the path I went down for high school and college and
all that.
And then eighth grade, I was in volleyball practice and noticed, I didn't notice, but
my coach noticed that I was kind of being a little more clumsy and uncoordinated.
And slowly but surely, I got benched permanently.
I was angsty and 14, so I was like, I hate sports because they hate me.
I pivoted and went into high school to do focusing on art and kind of went into more
of a party life, I guess, if you had to categorize me, because I was very angry at the world.
And it wasn't until my coordination got so bad that I realized I could no longer successfully
carry a cup of coffee or walk upstairs without a railing present.
And then my principal started smelling my breath for alcohol in the morning because
she thought I was coming to school drunk, which I kind of didn't realize was super odd
at the time.
And I went and told my mom that I thought something was wrong and I wasn't sure and
I think I needed to go to the doctor.
But my older sister had medical issues that had already been addressed, like she had surgery
on her spine for scoliosis and stuff like that.
So her gait was odd as well.
They blamed it on that.
And so when I started complaining, I was told I was copying my sister, would get in trouble
for trying to get attention.
And I thought maybe that was true.
Like I used to practice walking in a straight line in my room at night.
Like I thought I was losing my mind.
And then I turned 18 my senior year of high school and realized I could take myself to
the doctor.
I thought I had like an equilibrium problem, so I went to an ear, nose, and throat guy.
And eventually he ended up sending me to a neurologist.
And I had to tell my mom what I had been doing because her insurance did not cover that.
And so she agreed to pay for a genetic test if it would end my complaining.
I turned out to be right.
So who's laughing now?
Still everyone else.
Amazing.
And Dr. Lynch, could you talk a little bit about the beginning of your work in FA?
Because I took a look back at, I know you did a PhD in encephalins, you published extensively
on all sorts of neuropeptides, neuropharmacology, and I think it was around 2000, I think your
first FA paper shows up in the literature.
Talk about what happened back then and sort of when you first started experiencing this.
The funny part of it is, essentially someone walked into a conference room and said, hey,
I need someone for a project.
And I was volunteered by one of the other neurologists.
But then within the Friedreich-Ataxia field, there is an excellent advocacy organization
called the Friedreich-Ataxia Research Alliance.
And this required us to contact them.
And I got to know the people there, and it was just a very fun group of individuals to
work with.
So I kept diverting more and more of my time and more and more of my research effort toward
it.
So it's a series of coincidences, and then getting to know the people in the field and
liking the patient population so that you can actually dedicate what you do to it.
And Fiona, I've been watching a lot of your videos on YouTube, your Instagram channel,
and it's not just your comedy, which is spectacular, but your advocacy as well.
I mean, some videos you take us into medical exams.
I watched when you did a cardiac ultrasound recently.
You talked to the audience a lot about the condition.
You recently got engaged.
That was a very great story on a recent podcast.
Take us through sort of a typical day in your life.
What's it like living with FA?
And I know we see a lot of your successes, but tell us some of the sort of the sad days
as well, if you would.
Oh, man.
Well, I think a typical day now is very different than what it was two years ago for me, just
because of what I do for a living now.
I think maybe the less glamorous part of all this is traveling with a physical disability
is incredibly difficult.
I mean, just having a wheelchair and dealing with airlines feels like a battle every time
I do it.
Hotels, asking for an ADA room is shockingly difficult.
Seventy-five percent of the time, they don't have like a shower chair or a roll-in shower
available or yeah, yeah, that kind of stuff.
It is hard, I feel like, like in the medical community where y'all have done so many advances
and people are becoming more aware, but these day-to-day, just like pretty basic requirements
are still not being met and I'm not sure what that's about, but does that answer your question?
Absolutely.
And we'll get more into, we'll talk a little bit about sort of the medication that's out
there and some of what's being developed, but I want to just, Dr. Lynch, based on what
Fiona just mentioned, and I know that at CHOP, you've created this database of FFA and the
sake of course, because Fiona figured it out, went to the doctor, tested for this gene FXN,
which is this important protein that's involved in maintaining all the skeletal muscles normally.
Just talk about the condition and then just talk about what the typical sort of range
of presentation is, because I listened to one of your presentations recently talking
about depending on the degree of mutations involved with this FXN gene, that can dramatically
change the severity of the disorder across patients.
What typically do you see?
Is Fiona a typical patient in that continuum?
Walk us through a little of that for those that are unaware of this condition.
So it does have a range of presentations.
The youngest patient that I follow right now is age three.
They were actually predictably tested based on their seven-year-old sibling who had presented.
Usually you don't meet anyone who has symptoms below five.
Part of that being it's sort of indolent in its presentation.
It's a little slow.
Like Fiona said, people ascribe it to other stuff, in her case, scoliosis or middle child
syndrome, whatever she wants to ascribe it to, but it's a little bit indolent, so it's
hard to recognize.
It's not like you get hit by a sledgehammer.
So it's a little harder to find at the beginning, and most people have their first symptoms
of four age 10.
But then there's a very long tail where the oldest person had his first symptoms at age
65.
He's now 93.
He still tells me he plays golf.
He's moved south for obvious reasons, because many people do at that age, but he still plays
golf.
He doesn't keep score anymore, but he plays golf, and you see a very big range for that.
Mainly young.
Fiona is on the end of the early onset group, just on the later side with first symptoms
of teenage years, and then being diagnosed in late teenage years.
People sometimes take a while to get to the answer.
In kids, it's progressing faster.
It gets recognized as a disease, and people get to the answer within two or three years
in most part, and while you'd like to do it within two or three months, it's two or three
years before everyone agrees that something is going on.
In adults, one of the studies from Ferris suggested that it's 10 years on average for
the people who show up and get diagnosed at age 30, because it was so slow to change.
If it's not common in pediatric populations, it's rare in adult populations.
You do see an extreme.
In general, the earlier we meet you, the more severe your disease will be.
Continuing along that, and I think it's important for the audience to know here, because we've
done a lot of episodes on rare disorders, but in this case, it's important to know
that we do now have one FDA-approved product, something known as omoveloxalone.
Doctors, could you introduce a little bit of, I mean, this is not a cure for this condition,
but it is a major improvement over where we've been, involves both pro-inflammatory component
of the disease and the oxidative stress component.
Walk us through what the approved product does currently, and then we'll hop back over
to Fiona, because I have a lot of her involvement in marketing.
Sure.
So, OMAV, for short, and for obvious reasons, I call it OMAV, acts part of the pathophysiology
of the disease.
So, in free radical taxa, you have decreased levels of this protaxin protein.
It essentially helps you produce energy, but it also leads to what we think of as free
radical production, or reactive oxygen species production.
We all can protect ourselves against that, but for some reason, it's paradoxical.
In FA, people, that response doesn't turn on.
This drug turns it back on.
So, that's what it's doing at the molecular level.
What does it actually do to patients?
The way I present it to people is, on average, in an adult population, you'll go back a year
in time, you'll stay there for about a year, and then you'll progress at a slower rate.
That is not a cure.
Is it a good drug?
Yeah, it's a good drug.
And some people, a very good drug, the people who really respond, but it's far from a cure.
It does improve, it clearly improves people's energy.
The best description I had was a young woman who said that she was in college.
She was too tired all the time to take more than three classes.
On drug, she was able to take four classes and start a part-time job.
That's the best description of what it does for someone's life.
And it's been very similar, now that we've had it on the market, as it was in the clinical trial.
So, I am encouraged by that, and the clinical trial gave me the right results.
It's also pretty well tolerated.
Not a lot of people have to drop it.
And Fiona, I mean, I know, and I'd like you to take us into sort of the last couple weeks,
because I know you were over in Cairns, and for those in a way, we think of the Cairns Film Festival,
but there is also this Cairns Lions Festival involved in the advertising and communications industry.
And there was a big campaign and a focus group that you were involved in over there in France,
you know, focused on the drug, but also a very unique way.
And again, this comes to using comedy, not just to advocate for disease education,
but also as an entirely new way to market products.
Tell us a little bit, I mean, if you can say anything about your own experience with the product, that's great.
But, you know, talk a little bit about what you've been doing the last couple of weeks.
I think this is an extremely important time, let's say, in the way products are marketed.
And, you know, the education happens in this industry, which has been very old school the last hundred years.
Definitely. I mean, so I've been taking Striglaris for, I'd say, maybe a year and a half now.
And yeah, like Dr. Lynch said, it's kind of hard.
I try to tell people, if you're not noticing much, that's good.
Like, I'm not, I'm not, there's nothing I could do that I can't do that I've paid attention to.
Do you know what I mean?
And then as far as the Cannes Festival, the Lion Festival goes, that was very, very cool.
So, yeah, they did a campaign called Free Drugs Back, or is that what you want me to talk about?
Absolutely, please.
Where I think what, like, the focus was, was they had seen some of my comedy online and just, like, joking,
like, using dark humor to kind of educate, which I've always been a really big advocate for,
because I think humor makes things more digestible, regardless of how hard it is to hear.
And they kind of ran with that and made this whole series about the guy who found F.A.R.,
what's the correct term, like, he identified it, I guess, an old German guy.
And they've, they've made it, they've made it really, like, a fun way to educate people.
And I think this is huge for, again, we're talking about such a specific disease that won't affect
a lot of people, but whenever it's information sort of shared in this way, a lot more people
are curious about it. And the word is getting out in ways that I don't think were possible prior.
Yeah, it was, it was a brilliant ad. And it was historical. And I encourage anyone to take a look
at it. I think it had something like 10 million views now over the last couple days. But yeah,
it's just a very impressive way to, again, that this, this industry has been based on kind of
very boring style of marketing, let's be honest, hundred years, but it was spot on. So that was,
you know, a beautiful example of how we can use laughter as a strategic marketing tool.
Douglas, let's, let's talk a little bit about, you know, so we have the OneApproved product,
your lab is doing quite a bit more at Children's Hospital. We mentioned the database, but
extensive work in biomarkers, in drug development, in animal models. Take a little time to walk
through sort of what the landscape is. It's about small molecules, it's about proteins,
it's about gene therapies. Where is the FA space going beyond this first product? Because
I mean, it's great we have our first product, but it'd be great to have 20 more.
So that's an easy question to answer. All of the above. And while we do a lot of the work,
I would, again, emphasize that a lot of the work is all sponsored and done with the help of the
advocacy group, the Friedreich Ataxia Research Alliance. So let's think about Friedreich
Ataxia. It's a, you don't make enough of that small protein for taxon, which is involved in
energy production or mitochondrial function. Anyone can figure out the two ways to treat
Friedreich Ataxia. Make your mitochondrial function better, which is what Omovaloxone
does to some degree, or make more for taxon, or get more for taxon in. So it's a simple
approach when you think about it. The things which make your mitochondria function better
usually are not as powerful, but they're much better tolerated. They're safe.
They tend to wear off because your body is smart. If we try and trick it,
it's going to go back to the way it thinks it's going to be, which, unfortunately,
in Freona's case is to have Friedreich Ataxia. It's going to want to go back to that state.
So things like OMAV will wear off over time. But you can, if you stack one after another on top of
it, it's easier to fool the body, and you're more likely to have maintained benefit. In contrast,
the other way is to make more for taxon. We, there are two gene therapy trials open right now,
one for the heart, one for both heart and brain. There are trials of restoring for taxon by
protein replacement, just injecting the protein. There are soon to be trials, hopefully, of drugs
that turn the gene, which is inactivated, the taxon gene, which is inactivated back on.
And then even there is an approach, which is not yet in people, to replace it by introducing,
taking a person's stem cells, correcting them in a dish, and then putting the stem cells back
in so they can restore for taxon. So I think we're working on all of those. And sometimes
I even combine the different modalities to try and make a super therapy. There are new trials
all the time. You do not find new therapies unless you do new trials. That's just the basic rule.
If you don't try, nothing gets better. Well, again, it's a very positive thing
that we do have an FDA approved product. And the fact that attention is being shined on it like
this, I think is just so unique. Fiona, what else are you involved in? Obviously, you just came back
from CANS. You've been touring quite a bit. What should we be on the lookout for as far as you,
not just your comedy, of course, but in all these other initiatives? Because you,
obviously, you're quite a bit going on. Tell us what we should be looking for
as we head further into 2025. I am doing a TEDx talk here in Nashville in August. So
I am currently working on that right now. I go back on the road next week for a while.
And I'm getting married in October. There you go.
And Dr. Lynch, I'm a little plug for Philly that your work is happening right down the street here
and where I live. But what's happening in the University City world, other initiatives,
collaborations? I know you have, as you also mentioned, you have other pharma sort of biotech
relationships that you're gestating. What else should we be on the lookout for in terms of you
and your lab? So I think there are a lot of things we're working on now. Obviously,
everyone knows about our involvement in clinical trials and developing new clinical outcome
measures. We're also, again, going back. One of the questions is, why haven't we found more stuff
in the 25 years? We can kick ourselves a little bit. In some cases, I think it's because there
is more to Friedreich ataxia than that simple model of missing a mitochondrial protein, which
is involved in energy production, and then moving it forward. There are things we don't yet understand.
For example, one of the strange things is if we looked at the genetic tests and said
15% of all people with Friedreich ataxia have a certain weird phenomenon. It's a very technical
part. I'm not going to tell too much about it, but it just couldn't happen. So we worked with
Dr. B.D. Chandani at the University of Oklahoma, and we discovered basically about 15% of the genes
for FAA were missing. We found a couple people with FAA who weren't positive for the genetic test,
and we know that about 15% of carriers are missed by the commercially available genetic test,
which has caused us to go back, and I'm just trying to understand the biology more, but also
perfect the tests that people look for to get diagnosed with FAA and to find out whether
they're carriers, which is important in the case of genetic counseling for passing the gene on.
So that's something we're working on. We're looking for new functions for the ataxia molecule,
and I think we may have stumbled on one. So there's a lot of stuff going on, and each time
we have a very basic finding, it can lead to new therapies which are fundamentally different
than what you worked on before. And final message from you. I know that one of your
taglines, if we don't laugh, we cry, and I've cried enough, and I think this was the spark
that led to the current campaign. Any final messages in terms of
what we should be looking forward for as we get into the new year? Any other messages while we
I think don't focus on what you can't do, and focus on what you can,
and keep moving. And whatever that looks like, there are a million ways to get to the same place.
Awesome. Awesome. Well, you know, it was great having you both to touch on, you know,
a really unique area that we don't normally get into, but I think it's beautiful that
the ability to bring together comedy, the ability to bring together science,
and ultimately generate new awareness in an area like this is so crucial. So,
you know, it was great having both of you to discuss this really unique topic. Again,
for everybody listening to this episode of the show, across the podcast networks who will be
watching on the YouTube channel, we've been spending time with Fiona Cauley and Dr. David
Lynch. Fiona, David, I want to really thank you both for taking the time to come on the show today
to talk for a little while about this space. Thank you for everything you both are doing
to generate awareness, to generate the future of the technology. And as we like to say on our show,
thanks for helping to create a better tomorrow for many people out there that are just hearing
this story for the first time. Really, really an awesome story. It's great having both of you.
Thank you for having us, Ira.
Yeah, thank you.
Great having you.